Traws Pharma, Inc. Share Price
NASDAQ: TRAW | Micro Cap$0.34
+$0.34 (--%) Last updated on 27 Oct, 2026 | 23:25 ISTTraws Pharma, Inc. Stock Performance
Traws Pharma, Inc. Share Price Chart
$0.31$0.32
L
H
Traws Pharma, Inc. Quarterly Profit & Loss
All figures in USD
Traws Pharma, Inc. Annual Profit & Loss
All figures in USD
About Traws Pharma, Inc.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Traws Pharma, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $0.56 | $0.31 | -48.33% |
Sep 2026 | $0.56 | $0.60 | +13.21% |
Aug 2026 | $0.45 | $0.53 | +18.04% |
Jul 2026 | $0.82 | $0.45 | -45.38% |
Jun 2026 | $1.47 | $0.82 | -43.51% |
May 2026 | $1.45 | $1.46 | +2.46% |
Apr 2026 | $1.73 | $1.42 | -20.67% |
Mar 2026 | $1.51 | $1.79 | +9.15% |
Feb 2026 | $2.04 | $1.64 | -23.72% |
Jan 2026 | $1.17 | $2.15 | +95.45% |
Dec 2025 | $2.73 | $1.10 | -59.26% |
Nov 2025 | $2.57 | $2.70 | +6.51% |